Loxegen began when the founder's son was born with cystic fibrosis.
There are more than two thousand mutations of the CF gene, and Andrew's son has one of the rare ones — which, at the time, meant gene therapy was the only realistic hope. Life expectancy then was around twenty-five years. The mission was not academic, and it was not patient.
Andrew moved to London to sit with the Gene Therapy Consortium and help raise the money for a Phase 2b clinical trial of a lipid-based approach. He later met Dan Levy at the J.P. Morgan healthcare conference, and the approach that became Vectranox was explored for the first time.
The chemistry was originally built for systemic siRNA delivery. It was retooled — toward plasmid DNA, and away from systemic administration toward local, topical delivery, which is where the particle's properties actually made sense: cross a mucus barrier, reach an epithelium, express locally, and do it again next week. That became an inhaled gene therapy programme for cystic fibrosis, supported by Australia's Medical Research Future Fund alongside the University of Queensland and the Murdoch Children's Research Institute.
The research product came out of frustration. Working in the hardest models — differentiated airway epithelium at air–liquid interface, primary cells from children with CF — we kept hitting the same wall: when an experiment failed, there was no way to tell whether the construct was wrong or the delivery had simply never worked. The available positive controls did not transfect these models at all. So we used our own particles, and they did.
That is what Vectranox is. Not a therapeutic scaled down, and not a reagent scaled up — a delivery system built for the models where delivery is genuinely hard, offered to the people who have the same problem we did.
The particle today is several generations past those early experiments: structure–activity optimisation across peptide architecture and PEG chemistry, six-month room-temperature stability, reproducible batches, and independent replication at four institutions. The science has moved a long way. The reason has not.
The lead peptide was selected on structure–activity data, through a formal down-selection, by a team. Its code is 2904X. It corresponds to his son's birthday. Andrew had a hunch, from earlier SAR, that it might be the one. He did not know. 1512X — the peptide now being optimised for RNA — is named for his daughter's birthday. That one was by choice.
Andrew's son carries two copies of N1303K. It is also the genotype of the cells in which Vectranox delivered CFTR and restored chloride function up to three-fold — the functional data on this site was generated in cells carrying his mutation.
Last year N1303K was added to the Pharmaceutical Benefits Scheme, and he now receives Trikafta. For him, the urgency that started this company has eased. It has not eased for the roughly one in ten people with CF for whom modulators do not work. And it never applied at all to the many other diseases where the obstacle is not the gene — it is getting the gene where it needs to go.
